KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Acquisitions (2016 - 2019)

Edwards Lifesciences has reported Acquisitions over the past 6 years, most recently at $65.2 million for Q2 2019.

  • Quarterly results put Acquisitions at $65.2 million for Q2 2019, changed N/A from a year ago — trailing twelve months through Sep 2020 was $65.2 million (down 34.93% YoY), and the annual figure for FY2019 was $100.2 million, changed.
  • Acquisitions for Q2 2019 was $65.2 million at Edwards Lifesciences, up from $35.0 million in the prior quarter.
  • Over the last five years, Acquisitions for EW hit a ceiling of $320.8 million in Q3 2015 and a floor of -$200000.0 in Q1 2017.
  • Median Acquisitions over the past 4 years was $11.5 million (2015), compared with a mean of $57.5 million.
  • Peak annual rise in Acquisitions hit 4220.0% in 2017, while the deepest fall reached 110.0% in 2017.
  • Edwards Lifesciences' Acquisitions stood at $11.5 million in 2015, then plummeted by 78.26% to $2.5 million in 2016, then skyrocketed by 4220.0% to $108.0 million in 2017, then crashed by 39.63% to $65.2 million in 2019.
  • The last three reported values for Acquisitions were $65.2 million (Q2 2019), $35.0 million (Q1 2019), and $108.0 million (Q4 2017) per Business Quant data.